Pillar[n]arenes versus cyclodextrins as supramolecular carriers for improved bioavailability: Idebenone as a model drug
The present study describes the ability of different water soluble pillararenes (PAs) to complex and solubilize Idebenone (IDE), as a model drug, and the results are compared to previously reported complexes of IDE with cyclodextrins (CDs). We show that P[5]As strongly bind IDE, with the CDs showing lower binding and P[6]As exhibiting the weakest binding. The differences between the weak and strong complexes reached above two orders of magnitude in the binding constants. The solubility-permeability interplay was then investigated to determine the best structures for potential improvement of bioavailability under different circumstances. For unsaturated solutions, using an in-vitro BBB permeability model, the highest permeability was obtained with the weakest complexes, demonstrating the solubility-permeability interplay whereby higher binding leads to lower permeability. However, when saturated solutions/suspensions were used, with the oral in-vitro permeapad® permeability model, stronger complexes led to higher permeation and drug flux. By comparing to cyclodextrins we show that PAs may be a significant addition to the CDs family, commonly used for bioavailability improvement in pharmaceutical applications.
Authors
- Inbar Horin
- Dina Yeffet
- Yossi Zafrani (ORCID: https://orcid.org/0000-0001-5977-528X)
- Ishay Columbus (ORCID: https://orcid.org/0000-0001-6620-6966)
- Maya Hadar
- Boris Smolkin (ORCID: https://orcid.org/0000-0001-9383-8977)
- Yoram Cohen (ORCID: https://orcid.org/0000-0002-9442-8547)
- Dana Kaizerman‐Kane
- Sigal Saphier (ORCID: https://orcid.org/0000-0002-1784-3827)
Institutions
- Israel Institute for Biological Research (IL)
- Tel Aviv University (IL)
Publication Details
- Journal
- International Journal of Pharmaceutics
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1016/j.ijpharm.2025.126119
- Primary Topic
- Supramolecular Chemistry and Complexes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Israel Science Foundation